Galectin Therapeutics Inc.

NASDAQ: GALT · Healthcare · Biotechnology

PublicHQ Norcross, GA · GwinnettCIK 0001133416Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 19DQ —GM —SS 59

v0.1 · 35/100 weight · pillars only

↑ listing tenure, market scale · ↓ balance-sheet leverage, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$30.8M

Employees

as of 2026-08-13

Market cap

$206.8M

as of 2026-08-13

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$30.8M-$30.8M2025

Operating income-$20.1M-$20.1M2025

Total assets$19.5M$19.5M2025

Liabilities$145.7M$145.7M2025

Equity-$127.9M-$127.9M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Galectin Therapeutics Inc.’s financial profile?

Galectin Therapeutics Inc. earned -$30.8M in FY2025 net income.

Peers · Healthcare

Greenwich LifeSciences, Inc.——Immunic, Inc.——AN2 Therapeutics, Inc.——PepGen Inc.——Cardiol Therapeutics Inc.——Atrium Therapeutics, Inc.——

Neighbors

Gwinnett →

Primerica, Inc.$3.3B77B+AGCO Corporation$10.1B63C National Vision Holdings, Inc.$2.0B58C Fox Factory Holding Corp.$1.5B46D OneWater Marine Inc.$1.9B45D Guided Therapeutics, Inc.$767.0k42D

Key facts

CEOJoel Lewis

SectorHealthcare

IndustryBiotechnology

HeadquartersNorcross, GA

ExchangeNASDAQ: GALT

Employees9

IPO date2002-09-04

Latest filings

10-Q2026-08-14 8-K2026-08-14 8-K2026-08-04 8-K2026-06-23 10-Q2026-05-15 8-K2026-05-15 8-K2026-03-31 10-K2026-03-31

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.